David Zaccardelli, Verona Pharma CEO
August 10, 2022 10:02 AM EDTUpdated 10:26 AM
Financing

On heels of pos­i­tive COPD read­out, Verona to pro­vide new pub­lic of­fer­ing

Paul Schloesser

Associate Editor

Af­ter Verona Phar­ma’s COPD drug can­di­date proved to be ef­fec­tive in clin­i­cal tri­als and sent in­vestors scur­ry­ing to get in on the ac­tion, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times